Core Points - Glucotrack, Inc. will reconvene a Special Meeting of Shareholders on November 7, 2025, to vote on an Equity Purchase Agreement with Sixth Borough Capital Fund [1][2] - The company encourages shareholders to vote as soon as possible to comply with NASDAQ Listing Rule 5635(d), which allows the issuance of more than 20% of the company's outstanding Common Stock through a $20 million Purchase Agreement [2] - Shareholders of record as of September 23, 2025, are eligible to vote, and the company provides multiple voting methods including telephone and online options [3][4] Voting Recommendations - The Board of Directors unanimously recommends that shareholders vote "FOR" all proposals, emphasizing the importance of every vote [5] - Shareholders are encouraged to ensure that all their accounts are voted to represent their shares fully [4] Additional Information - Detailed information regarding the proposals can be found in the definitive proxy statement filed with the SEC on October 3, 2025 [6] - Shareholders needing assistance with voting can contact the company's proxy solicitation firm, Sodali & Co. [7] Company Overview - Glucotrack, Inc. focuses on developing novel technologies for diabetes management, including a long-term implantable continuous blood glucose monitoring system [8] - The company's continuous blood glucose monitoring (CBGM) system is designed for a sensor longevity of 3 years, with minimal calibration required [9]

Core Points - Glucotrack, Inc. will hold a Special Meeting of Shareholders on October 31, 2025, to vote on an Equity Purchase Agreement with Sixth Borough Capital Fund [1] - Shareholders of record as of September 23, 2025, are eligible to vote, and the company encourages prompt voting [2] - The Board of Directors recommends that shareholders vote "FOR" all proposals to ensure their shares are represented [4] Voting Information - Shareholders can vote via telephone, online, or by returning a completed proxy card [2] - Those holding shares in multiple accounts will receive separate voting materials and must vote for each account [3] - Additional details regarding the proposals are available in the definitive proxy statement filed with the SEC on October 3, 2025 [5] Company Overview - Glucotrack, Inc. focuses on developing novel technologies for diabetes management, including a long-term implantable continuous blood glucose monitoring system [7] - The Glucotrack CBGM system is designed to measure blood glucose levels continuously with a sensor longevity of 3 years and minimal calibration [8]

Core Insights - Glucotrack, Inc. is participating in the Q3 Virtual Investor Summit on September 16-17, 2025, where management will present and hold one-on-one meetings with investors [1][2]. Company Overview - Glucotrack, Inc. (NASDAQ: GCTK) focuses on the design, development, and commercialization of innovative technologies for diabetes management [2]. - The company is developing a long-term implantable continuous blood glucose monitoring system aimed at improving the lives of people with diabetes [2]. Product Details - The Glucotrack Continuous Blood Glucose Monitoring (CBGM) system is designed to measure blood glucose levels continuously, featuring a sensor longevity of 3 years, no on-body wearable component, and minimal calibration requirements [3]. - The CBGM is currently classified as an Investigational Device and is limited to investigational use under U.S. law [3].